Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Lusutrombopag

Myelodysplastic syndrome, pancytopenia, decreased platelet count, haematemesis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is: Drug overdose Drug interaction
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yoshiji H, et al. Safety and effectiveness of lusutrombopag in patients who have chronic liver disease with thrombocytopenia and undergoing invasive procedures: Real-world post-marketing surveillance in Japan. Hepatology Research 53: 1105-1116, Nov 2023. Available from: URL: https://dx.doi.org/10.1111/hepr.13945 Yoshiji H, et al. Safety and effectiveness of lusutrombopag in patients who have chronic liver disease with thrombocytopenia and undergoing invasive procedures: Real-world post-marketing surveillance in Japan. Hepatology Research 53: 1105-1116, Nov 2023. Available from: URL: https://​dx.​doi.​org/​10.​1111/​hepr.​13945
Metadaten
Titel
Lusutrombopag
Myelodysplastic syndrome, pancytopenia, decreased platelet count, haematemesis
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56352-x

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Siltuximab

Case report

Pembrolizumab

Case report

Nivolumab